OP38 Maintenance treatment with mirikizumab, a p19-directed IL-23 antibody: 52-week results in patients with moderately-to-severely active ulcerative colitis | Zendy

AI Assistant Blog Pricing

OP38 Maintenance treatment with mirikizumab, a p19-directed IL-23 antibody: 52-week results in patients with moderately-to-severely active ulcerative colitis

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.